Medication Guide App

Netupitant and palonosetron Approval Status

Netupitant and palonosetron is an investigational oral fixed-dose combination of the selective NK1 receptor antagonist netupitant and the 5-HT3 receptor antagonist palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV).

FDA Approval Status for netupitant and palonosetron

Jan 12, 2011FDA Agrees to Special Protocol Assessment (SPA) to Evaluate the Safety and Efficacy of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINV

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.